RESULTS: On IVA adjusting for socio-demographic, facilityand tumor-specific covariates, RP was associated with lower overall mortality compared to RT+ADT (hazard ratio (HR) 0.52; 95% CI, 0.47-0.57; p<0.001) in the overall analysis, in patients with age ¼65 years with CCI 0 (HR 0.48; p<0.001), in patients >65 years with CCI 0 (0.53; p<0.001), those receiving RT with neoadjuvant (HR 0.52; p<0.001) or adjuvant ADT (HR 0.47; p<0.001), or treated with high dose (¼75.6 Gy) RT (HR 0.54; p<0.001). While the survival outcomes for patients treated with RT (+/-ADT) in the RCTs were not statistically different from similarly treated and appropriately selected patients within the NCDB, RP was associated with greater overall mortality-free survival than any of the arms represented in the RCTs.
INTRODUCTION AND OBJECTIVES: Among the different approaches to treat recurrent prostate cancer only 2% of the patients undergo salvage RP because, despite good cancer control, historically, salvage RP has been associated with significant morbidity and poor functional outcomes. To analyze the learning curve in terms of morbidity, oncological and functional outcomes in Salvage Robotic Assisted Radical Prostatectomy (sRARP) patients in a single surgeon tertiary-referral center.
METHODS: In our IRB approved retrospective analysis >9000 patients underwent RARP for localized prostate cancer (PCa) by a single surgeon (V.P) between January 2008 and March 2016. Among those patients, 80 underwent sRARP due to a local recurrence after primary treatment. Within the current learning curve analysis, all of the 80 sRARP patients were then sub-divided in 4 equal groups of 20 consecutive patients based on date of surgery. Functional and oncological outcomes were measured at 12 months post-sRARP in Groups 1-3 only, as group 4 had limited follow-up. Potency was defined as the ability to achieve a successful erection with penetration over 50% of the time, while full and 0-2 continence was defined as 0 pads and ¼2 pads/ day, respectively. RESULTS: Preoperatively; a trend to decrease was observed through the 4 groups in terms of operative time (137 to 125 min; p¼0.022), estimated blood loss (137 to 117ml; p¼0.346) and catheterization time (16.95 to 12.2; p¼0.182). Radiographic anastomotic leaks trended towards a decline (from 50% to 20%; p¼0.126), while morbidity remained stable thorough the groups (5%; p>0.05). Biochemical failure was similar between 3 groups (30%, 31.3%, and 21.4% respectively: p¼0.797) and all patients were alive at 12 months of follow up. Potency rates tended to increase from 10% in GI to 28.6% in GIII (p¼0.378). Full and 0-2pads continence rates were similar among the groups (50-57.9%; p¼0.859 and 60-68.4%: p¼0.860 respectively). Lastly; a clinical reduction in time to continence was observed from GI to GIII (112.3 to 71.28 days; p¼0.393).
CONCLUSIONS: The learning curve over the course of~8 years demonstrated a decrease in operative time and suggested a trend for decreases in intraoperative blood loss, catheterization time and anastomotic leaks, while nerve sparing increased significantly through the groups. Therefore, a slightly higher potency rate and lower time to continence through the learning curve was shown. However, longer term studies are needed to confirm these results.
Source of Funding: None

PD51-07
IMPACT OF THE TIME INTERVAL BETWEEN BIOPSY AND ROBOTIC-ASSISTED RADICAL PROSTATECTOMY ON BIOCHEMICAL RECURRENCE: A PROPENSITY SCORE MATCHING ANALYSIS Yosuke Hirasawa*, Makoto Ohori, Naoto Kaburagi, Takashi Mima, Tatsuo Gondo, Tokyo, Japan; Kunihiko Yoshioka, Kanagawa, Japan; Jun Nakashima, Yoshio Ohno, Tokyo, Japan INTRODUCTION AND OBJECTIVES: The impact of the time interval (TI) between prostate biopsy and robot-assisted radical prostatectomy (RARP) on the risk of biochemical recurrence (BCR) has been controversial so far. It is possible that clinicians empirically decide on curative treatments earlier for patients who are expected to have a worse prognosis, resulting in a so-called treatment selection bias. Therefore, we performed propensity score matching analysis to investigate the potential impact of treatment delays in patients with localized prostate cancer.
METHODS: We retrospectively reviewed the medical records of 812 patients who were treated with RARP at our institution. A multivariate Cox analysis was used to identify the independent significant preoperative risk factors for BCR. Using these preoperative risk factors, a propensity score matching analysis was conducted to adjust for the preoperative characteristics between two patient groups: Group A, TI 6 months; Group B, TI 6 months). Clinicopathological outcomes and BCRFS between the two groups were compared to investigate the impact of TI 6 months on oncological outcomes after RARP.
RESULTS: The median follow-up period after RARP was 32.2 months (6.1-104.9 months). The multivariate analysis revealed that PSA, primary (pGS) and secondary (sGS) Gleason score, and a positive prostate biopsy were independent preoperative risk factors for BCR. One hundred and two patients with Group B were matched with an equal number of patients with Group A based on propensity scores by using six preoperative factors: PSA, pGS and sGS, clinical T stage, age, and positive prostate biopsy. The propensity adjusted 5-year BCRFS for patients with TI 6 months was 85.5%. This was not worse than that of patients with TI 6 months (85.0%, p ¼ 0.85). Similarly for D 0 Amico low-risk patients, the propensity adjusted 5-year BCRFS rates for Group A and Group B were 99.2% and 99.4%, respectively (p ¼ 0.84); for intermediate-risk patients, 89.1% and 79.6%, respectively (p ¼ 0.19); and for high-risk patients, 69.9% and 89.1%, respectively (p ¼ 0.36). There were no significant differences with regards to Gleason upgrading (p ¼ 0.46) or upstaging (p ¼ 0.11) after propensity adjustments between the two groups.
CONCLUSIONS: In our cohorts, a delay in the time from biopsy to RARP did not significantly affect BCR. Therefore, hasty treatment decisions are unnecessary for at least 6 months after biopsy of early prostate cancer. However, we suppose that our results may not be same for patients with very high-risk/locally advanced cancer.
